Merck, a leading science and technology company, today announced that data for approved and investigational multiple sclerosis (MS) treatments, MAVENCLAD ® (Cladribine Tablets) and Rebif ® (interferon ...
ROCKLAND, Mass., April 13, 2018 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, today announced data for Cladribine Tablets, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback